iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Company Overview - Insight Molecular Diagnostics, or iMDx, is a pioneering diagnostics technology company focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [8] - The company recently moved its headquarters from Irvine, California, to Nashville, Tennessee, with a new NASDAQ symbol effective June 18, 2025 [9] Key Opinion Leader Event - iMDx will host a virtual key opinion leader (KOL) event on August 15, 2025, featuring Dr. Anthony Langone, who is the national principal investigator for iMDx's kidney transplant monitoring trial [1][2] - Dr. Langone will discuss the role of donor-derived cell-free DNA (dd-cfDNA) in transplant care and the benefits of in-house testing [2] GraftAssure™ Product Line - The GraftAssure™ family of assays utilizes advanced digital PCR (dPCR) technology to provide reliable dd-cfDNA results for transplant monitoring [3] - The company is developing a diagnostics test kit for clinical use, allowing hospitals to conduct their own tests in-house [3] - Current products include GraftAssureCore, a lab-developed test reimbursed by CMS, and GraftAssureIQ, a research-use-only kit [6][7] Future Developments - iMDx is working on GraftAssureDx, an in vitro diagnostic kit intended for clinical decision-making, which will be submitted for FDA authorization [7] - The company aims to commercialize its technology using a market-disruptive approach, establishing dd-cfDNA as a trusted biomarker for transplant rejection [6]